Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC

by Dong, Xiaorong , Cronemberger, Eduardo , Ahn, Myung-Ju , Wang, Chih-Liang , Sriuranpong, Virote , Ghiorghiu, Dana , Quang, Le-Van , Runglodvatana, Yotsawaj , van der Gronde, Toon , Huang, Xiangning , Ramalingam, Suresh S. , Chen, Ming , Kato, Terufumi , Inoue, Takako , Khiem, Dang-Van , Takahashi, Toshiaki , Cobo, Manuel , Yang, James Chih-Hsin , Huang, Meijuan , Grainger, Ellie , Lu, Shun , Casarini, Ignacio , Özgüroğlu, Mustafa , Soparattanapaisarn, Nopadol

in Acrylamides - adverse effects / Acrylamides - therapeutic use / Adult / Aged / Aged, 80 and over / Aniline Compounds - adverse effects / Aniline Compounds - therapeutic use / Antineoplastic Agents - adverse effects / Antineoplastic Agents - therapeutic use / Cancer therapies / Carcinoma, Non-Small-Cell Lung - genetics / Carcinoma, Non-Small-Cell Lung - mortality / Carcinoma, Non-Small-Cell Lung - pathology / Carcinoma, Non-Small-Cell Lung - therapy / Chemoradiotherapy / Chemoradiotherapy - adverse effects / Chemoradiotherapy - methods / Chemotherapy / Critical Care / Critical Care General / Double-Blind Method / Epidermal growth factor receptors / ErbB Receptors - antagonists & inhibitors / ErbB Receptors - genetics / Female / Hematology / Humans / Indoles / International organizations / Kaplan-Meier Estimate / Lung Cancer / Lung Neoplasms - genetics / Lung Neoplasms - mortality / Lung Neoplasms - pathology / Lung Neoplasms - therapy / Magnetic resonance imaging / Male / Metastasis / Middle Aged / Mutation / Neoplasm Staging / Non-small cell lung carcinoma / Oncology / Placebos / Pneumonitis / Progression-Free Survival / Pulmonary / Pyrimidines / Radiation therapy / Small cell lung carcinoma / Statistical analysis / Targeted cancer therapy / Treatments in Oncology / Tumors / Tyrosine Kinase Inhibitors - adverse effects / Tyrosine Kinase Inhibitors - therapeutic use

2024

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC

2024

Confirm

Do you wish to request the book?

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC

2024

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC

Dong, Xiaorong,

Cronemberger, Eduardo,

Ahn, Myung-Ju,

Wang, Chih-Liang,

Sriuranpong, Virote,

Ghiorghiu, Dana,

Quang, Le-Van,

Runglodvatana, Yotsawaj,

van der Gronde, Toon,

Huang, Xiangning,

Ramalingam, Suresh S.,

Chen, Ming,

Kato, Terufumi,

Inoue, Takako,

Khiem, Dang-Van,

Takahashi, Toshiaki,

Cobo, Manuel,

Yang, James Chih-Hsin,

Huang, Meijuan,

Grainger, Ellie,

Lu, Shun,

Casarini, Ignacio,

Özgüroğlu, Mustafa,

Soparattanapaisarn, Nopadol

2024

Overview

Among patients with EGFR -mutated lung cancer after chemoradiotherapy, 65% of patients who received osimertinib were alive without progression at 2 years, as compared with 13% of those who received placebo.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Acrylamides - adverse effects

/ Acrylamides - therapeutic use

/ Adult

/ Aged

/ Aged, 80 and over

/ Aniline Compounds - adverse effects

/ Aniline Compounds - therapeutic use